Fibrocell Science Inc (FCSC)

0.81
0.01 1.20
NASDAQ : Health Care
Prev Close 0.80
Open 0.85
Day Low/High 0.80 / 0.85
52 Wk Low/High 0.91 / 7.60
Volume 47.17K
Avg Volume 208.50K
Exchange NASDAQ
Shares Outstanding 43.98M
Market Cap 36.94M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Fibrocell Announces Leadership Changes

Fibrocell Announces Leadership Changes

Fibrocell Appoints Alfred T. Lane, MD, Chief Medical Advisor

Fibrocell Appoints Alfred T. Lane, MD, Chief Medical Advisor

Respected Clinician and Researcher Focused on Developing Therapies for Epidermolysis Bullosa

Fibrocell Reports Third Quarter 2016 Financial Results And Recent Operational Highlights

Fibrocell Reports Third Quarter 2016 Financial Results And Recent Operational Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT

Fibrocell Announces Convertible Debt And Warrant Financing of Up To $25 Million

Fibrocell Announces Convertible Debt And Warrant Financing of Up To $25 Million

Terminates Previously Announced Underwritten Public Offering

Fibrocell Reports Second Quarter 2016 Financial Results And Recent Operational Highlights

Fibrocell Reports Second Quarter 2016 Financial Results And Recent Operational Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT

Fibrocell Science Stock Sees Short Interest Decrease By 24.4%

Fibrocell Science Stock Sees Short Interest Decrease By 24.4%

The most recent short interest data has been released for the 06/15/2016 settlement date, which shows a 845,388 share decrease in total short interest for Fibrocell Science, Inc. , to 2,622,567, a decrease of 24.38% since 05/31/2016.

These 5 Stocks Under $10 Are Set to Soar Higher

These 5 Stocks Under $10 Are Set to Soar Higher

Here's a technical look at how to trade several under-$10 stocks that are poised for breakouts.

Fibrocell Reports First Quarter 2016 Financial Results And Operational Highlights

Fibrocell Reports First Quarter 2016 Financial Results And Operational Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT

Fibrocell Receives Orphan Drug Designation From The FDA For FCX-013 For The Treatment Of Localized Scleroderma

Fibrocell Receives Orphan Drug Designation From The FDA For FCX-013 For The Treatment Of Localized Scleroderma

FCX-013 Gene-Therapy Product Candidate Offers Potential to Address Painful Fibrotic Disease

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stock look poised to break out and trade higher from current levels.

Fibrocell Reports Fourth Quarter And Full Year 2015 Financial Results And Operational Highlights

Fibrocell Reports Fourth Quarter And Full Year 2015 Financial Results And Operational Highlights

Company to Host Conference Call and Webcast, Today at 8:30 a.m. EST